Your browser doesn't support javascript.
loading
Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.
Ray, Kausik K; Leiter, Lawrence A; Müller-Wieland, Dirk; Cariou, Bertrand; Colhoun, Helen M; Henry, Robert R; Tinahones, Francisco J; Bujas-Bobanovic, Maja; Domenger, Catherine; Letierce, Alexia; Samuel, Rita; Del Prato, Stefano.
Afiliación
  • Ray KK; Department of Primary Care and Public Health, Imperial Centre for Cardiovascular Disease Prevention, Imperial College, London, UK.
  • Leiter LA; Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
  • Müller-Wieland D; Department of Internal Medicine I, University Hospital Aachen, Aachen, Germany.
  • Cariou B; Department of Endocrinology, l'institut du thorax, CHU Nantes, Nantes, INSERM, CNRS, UNIV Nantes, Nantes, France.
  • Colhoun HM; University of Edinburgh, Edinburgh, UK.
  • Henry RR; University of California San Diego School of Medicine and Center for Metabolic Research, Veterans Affairs, San Diego Healthcare System, San Diego, California.
  • Tinahones FJ; Department of Clinical Endocrinology and Nutrition (IBIMA), Hospital Virgen de la Victoria, University of Málaga, CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III, Málaga, Spain.
  • Bujas-Bobanovic M; Sanofi, Paris, France.
  • Domenger C; Sanofi, Gentilly, France.
  • Letierce A; Biostatistics and Programming Department, Sanofi, Chilly-Mazarin, France.
  • Samuel R; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
  • Del Prato S; Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Diabetes Obes Metab ; 20(6): 1479-1489, 2018 06.
Article en En | MEDLINE | ID: mdl-29436756
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inhibidores de Hidroximetilglutaril-CoA Reductasas / Diabetes Mellitus Tipo 2 / Dislipidemias / Hipoglucemiantes / Anticuerpos Monoclonales / Anticolesterolemiantes Tipo de estudio: Clinical_trials Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Diabetes Obes Metab Asunto de la revista: ENDOCRINOLOGIA / METABOLISMO Año: 2018 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inhibidores de Hidroximetilglutaril-CoA Reductasas / Diabetes Mellitus Tipo 2 / Dislipidemias / Hipoglucemiantes / Anticuerpos Monoclonales / Anticolesterolemiantes Tipo de estudio: Clinical_trials Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Diabetes Obes Metab Asunto de la revista: ENDOCRINOLOGIA / METABOLISMO Año: 2018 Tipo del documento: Article País de afiliación: Reino Unido